Hypertriglyceridemia Market to Grow Significantly By 2032 | Acasti Pharma Inc., JSS Medical Research Inc., Mochida Pharmaceutical Company Ltd., Sumitomo Pharma (Suzhou) Co. Ltd., and others.

{Delhi, India} To strategically aid Hypertriglyceridemia Companies in developing drugs for Hypertriglyceridemia, DelveInsight launched a report titled “Hypertriglyceridemia Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology-based market analysis, providing a roadmap for success in the dynamic landscape of the Hypertriglyceridemia Market.

Download a free sample copy of “Hypertriglyceridemia Market Report”

Key highlights from the Hypertriglyceridemia Market Report

• As per the assessment of DelveInsight, in 2022, there were approximately 69,607,255 Hypertriglyceridemia Diagnosed Prevalent Cases in the 7MM. These cases are expected to increase in the forecast period.
• The Hypertriglyceridemia Market Size in the 7MM was found to be around USD 2,400 Million in 2022. It will increase during the forecast period (2023–2032), owing to the launch of upcoming therapies.
• The leading companies working in the Hypertriglyceridemia Market include Acasti Pharma Inc., JSS Medical Research Inc., Mochida Pharmaceutical Company Ltd., Sumitomo Pharma (Suzhou) Co. Ltd., Ionis Pharmaceuticals Inc., Akcea Therapeutics, Matinas Biopharma Inc., Matinas BioPharma Nanotechnologies Inc., Essentialis Inc., Medpace Inc., Enzymotec, Daewon Pharmaceutical Co. Ltd, 89Bio Inc., Abbott, and others.
• Promising Hypertriglyceridemia Pipeline Therapies in the various stages of development include CaPre (TM), Ethyl Icosapentate, Volanesorsen, Omega 3 Pentaenoic Acid, Icosapent ethyl, ISIS 678354, Diazoxide choline, APOC-III-L-Rx, Olezarsen, and others.

Hypertriglyceridemia Country-based Treatment Analysis

The Hypertriglyceridemia treatment market report provides treatment regimens across the 7MM. It will help companies to analyze the practices followed across 7MM, the patient journey, and advances in Hypertriglyceridemia therapies that have the potential treatment paradigms and improve patient outcomes.

Hypertriglyceridemia is a medical condition characterized by elevated levels of triglycerides in the blood, a type of fat that plays a crucial role in energy storage. This disorder is often associated with metabolic abnormalities and can be a significant risk factor for cardiovascular diseases.

Download the report to understand which factors are driving Hypertriglyceridemia Epidemiology trends @ Hypertriglyceridemia Epidemiology Forecast

Hypertriglyceridemia Epidemiology Insights

The report proffers historical and forecasted epidemiology insights that help to understand the target patient population for Hypertriglyceridemia. The analysis is from 2019-2032, providing insights into how the patient trends are going to shape Hypertriglyceridemia market dynamics. Further, the epidemiology is segmented to provide an in-depth analysis of patient pools allowing companies to understand their target patient pools.

Hypertriglyceridemia Epidemiology Segmentation in the 7MM

• Hypertriglyceridemia Prevalent Cases
• Hypertriglyceridemia Severity-specific Diagnosed Prevalent Cases
• Hypertriglyceridemia Diagnosed Prevalent Cases
• Hypertriglyceridemia Etiology-specific Diagnosed Prevalent Cases

“According to DelveInsight analysis, the severity‐specific data reveal the highest number of cases were observed in a moderate level of HTG”

Hypertriglyceridemia Drugs and Companies

• Acasi Pharma Inc.: CaPre
• Sumitomo Pharma (Suzhou) Co. Ltd: Ethyl Icosapentate
• Ionis Pharmaceuticals Inc: Volanesorsen
• Matinas BioPharma Nanotechnologies Inc: Omega 3 Pentaenoic Acid
• Matinas Biopharma Inc: Icosapent Ethyl
• Akcea Therapeutics: ISIS678354

To learn more about Hypertriglyceridemia Companies working in the treatment market, visit @ Hypertriglyceridemia Clinical Trials and Therapeutic Assessment

Hypertriglyceridemia Treatment Landscape

For the Hypertriglyceridemia treatment, popular guidelines such as AHA/ACC lipid treatment guidelines recommend addressing and treating lifestyle factors, secondary factors such as diabetes mellitus, chronic liver or kidney disease, and/or Nephrotic syndrome, hypothyroidism, and medications that increase triglycerides. If serum triglycerides remain elevated even after optimizing these factors, pharmacological therapies are to be considered. The goal of drug treatment is to reduce the level of triglyceride and to reduce the risk of pancreatitis and cardiovascular disease in patients with severe hypertriglyceridemia.

Hypertriglyceridemia Drugs Uptake

Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of Apoc-III in the liver. Previously it was being investigated for familial chylomicronemia syndrome (FCS), but in late 2021, Ionis Pharmaceuticals also started an investigational study dedicated to Severe Hypertriglyceridemia patients.

Pegozafermin (BIO89-100) is engineered using a proprietary glycoPEGylation technology to prolong the biological activity of FGF21 while maintaining the efficacy of native FGF21—an endogenous metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. It is currently being developed for the treatment of nonalcoholic steatohepatitis (“NASH”) and the treatment of severe hypertriglyceridemia (“SHTG”).

ARO-APOC3 is designed to reduce the production of Apolipoprotein C-III (Apoc-III), a component of triglyceride-rich lipoproteins (TRLs) including VLDL and chylomicrons, and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.

Discover more about therapies set to grab major Hypertriglyceridemia Market Share @ Hypertriglyceridemia Treatment Market

Scope of the Hypertriglyceridemia Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2023-2032
• Hypertriglyceridemia Companies- Acasti Pharma Inc., JSS Medical Research Inc., Mochida Pharmaceutical Company Ltd., Sumitomo Pharma (Suzhou) Co. Ltd., Ionis Pharmaceuticals Inc., Akcea Therapeutics, Matinas Biopharma Inc., Matinas BioPharma Nanotechnologies Inc., Essentialis Inc., Medpace Inc., Enzymotec, Daewon Pharmaceutical Co. Ltd, 89Bio Inc., Abbott, and others.
• Promising Hypertriglyceridemia Pipeline Therapies- CaPre (TM), Ethyl Icosapentate, Volanesorsen, Omega 3 Pentaenoic Acid, Icosapent ethyl, ISIS 678354, Diazoxide choline, APOC-III-L-Rx, Olezarsen, and others.

Note:-

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Hypertriglyceridemia Market Landscape.

Gain Competitive Edge in the Indication Market: Understand the current landscape of the Hypertriglyceridemia Market, including the competitive environment, key companies developing drugs for Hypertriglyceridemia, and their strategies. By analyzing Hypertriglyceridemia market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the Hypertriglyceridemia Market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Hypertriglyceridemia. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the Hypertriglyceridemia market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

Plan Roadmap to Success: Through this report, the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Hypertriglyceridemia Market with clarity and purpose.

Read our Blogs- Pharmaceutical and Biotech Insight, News and Blog Posts

Related Reports

Hypertriglyceridemia Epidemiology Forecast 2032

DelveInsight's Hypertriglyceridemia - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hypertriglyceridemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hypertriglyceridemia Pipeline Insight 2023

Hypertriglyceridemia Pipeline Insights, 2023 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.

Hypertriglyceridemia Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Hypertriglyceridemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Hypertriglyceridemia.

Explore Our Success Story of Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study! 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/